{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:19:32Z","timestamp":1791231572983,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["4022475"],"award-info":[{"award-number":["4022475"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03116-z","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T15:03:05Z","timestamp":1751727785000},"page":"982-1001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antiphospholipid antibodies in patients with COVID-19: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5101-7078","authenticated-orcid":false,"given":"Mehrdad","family":"Rostami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-0272","authenticated-orcid":false,"given":"Mohammad","family":"Parsa-kondelaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8164-817X","authenticated-orcid":false,"given":"Mettine H. A.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4904-0156","authenticated-orcid":false,"given":"Hassan","family":"Mansouritorghabeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"3116_CR1","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1093\/ije\/dyac184","volume":"51","author":"NE Antonio-Villa","year":"2022","unstructured":"Antonio-Villa NE, Bello-Chavolla OY (2022) Socio-demographic inequalities and excess non-COVID-19 mortality during the COVID-19 pandemic: a data-driven analysis of 1 069 174 death certificates in Mexico. Int J Epidemiol 51:1711\u201321. https:\/\/doi.org\/10.1093\/ije\/dyac184","journal-title":"Int J Epidemiol"},{"key":"3116_CR2","unstructured":"WHO website accessible at: https:\/\/data.who.int\/dashboards\/covid19\/deaths. Acceessed on Oct 30, 2024."},{"key":"3116_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyad149","author":"MP Petit","year":"2024","unstructured":"Petit MP, Ouellette N, Bourbeau R (2024) The case for counting multiple causes of death in the COVID-19 era. Int J Epidemiol. https:\/\/doi.org\/10.1093\/ije\/dyad149","journal-title":"Int J Epidemiol"},{"key":"3116_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyae003","author":"NA van Westen-Lagerweij","year":"2024","unstructured":"van Westen-Lagerweij NA, Plasmans MHD, Kramer I, Harteloh PPM, Poos MJJC, Hilderink HBM, Croes EA (2024) bRisk of death due to COVID-19 among current and former smokers in the Netherlands: a population-based quasi-cohort study. Int J Epidemiol. https:\/\/doi.org\/10.1093\/ije\/dyae003","journal-title":"Int J Epidemiol"},{"key":"3116_CR5","doi-asserted-by":"crossref","unstructured":"Di Minno A, Ambrosino P, Calcaterra I, Di Minno MN (2020) COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost: Thieme Medical Publishers, 763\u201371.","DOI":"10.1055\/s-0040-1715456"},{"key":"3116_CR6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1001\/jama.2020.13372","volume":"324","author":"S Bilaloglu","year":"2020","unstructured":"Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS (2020) Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA 324:799\u2013801","journal-title":"JAMA"},{"key":"3116_CR7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1473-3099(20)30434-5","volume":"20","author":"L Carsana","year":"2020","unstructured":"Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, Rech R, Colombo R, Antinori S, Corbellino M (2020) Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 20:1135\u20131140","journal-title":"Lancet Infect Dis"},{"key":"3116_CR8","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/ajcp\/aqaa156","volume":"154","author":"S De Michele","year":"2020","unstructured":"De Michele S, Sun Y, Yilmaz MM, Katsyv I, Salvatore M, Dzierba AL, Marboe CC, Brodie D, Patel NM, Garcia CK (2020) Forty postmortem examinations in COVID-19 patients: two distinct pathologic phenotypes and correlation with clinical and radiologic findings. Am J Clin Pathol 154:748\u2013760","journal-title":"Am J Clin Pathol"},{"key":"3116_CR9","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/jth.14844","volume":"18","author":"M Dolhnikoff","year":"2020","unstructured":"Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, da Silva LFF, de Oliveira EP, Saldiva PHN, Mauad T, Negri EM (2020) Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost 18:1517\u20131519","journal-title":"J Thromb Haemost"},{"key":"3116_CR10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/thoraxjnl-2020-216243","volume":"76","author":"J Loo","year":"2021","unstructured":"Loo J, Spittle DA, Newnham M (2021) COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax 76:412\u2013420","journal-title":"Thorax"},{"key":"3116_CR11","first-page":"171","volume":"10","author":"EI Obeagu","year":"2023","unstructured":"Obeagu EI, Hamisi S, Bunu UO (2023) An update on cytokine storm in covid-19 infection: Pivotal to the survival of the patients. Int J Adv Res Biol Sci 10:171\u2013180","journal-title":"Int J Adv Res Biol Sci"},{"key":"3116_CR12","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s10072-023-06682-3","volume":"44","author":"U Pensato","year":"2023","unstructured":"Pensato U, Forlivesi S, Gentile M, Romoli M, Muccioli L, Ambrosi F, Foschini MP, Gallo C, Ballestrazzi MS, Teutonico P (2023) Carotid free-floating thrombus in COVID-19: a cerebrovascular disorder of cytokine storm-related immunothrombosis. Neurol Sci 44:1855\u20131860","journal-title":"Neurol Sci"},{"key":"3116_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.thromres.2023.01.016","volume":"223","author":"K W\u00f3jcik","year":"2023","unstructured":"W\u00f3jcik K, Bazan-Socha S, Celejewska-W\u00f3jcik N, G\u00f3rka K, Licho\u0142ai S, Polok K, Stachura T, Zar\u0119ba L, Dziedzic R, Gradzikiewicz A (2023) Decreased protein C activity, lower ADAMTS13 antigen and free protein S levels accompanied by unchanged thrombin generation potential in hospitalized COVID-19 patients. Thromb Res 223:80\u201386","journal-title":"Thromb Res"},{"key":"3116_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10456-023-09878-5","volume":"27","author":"X Wu","year":"2024","unstructured":"Wu X, Xiang M, Jing H, Wang C, Novakovic VA, Shi J (2024) Damage to endothelial barriers and its contribution to long COVID. Angiogenesis 27:5\u201322","journal-title":"Angiogenesis"},{"key":"3116_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.519","volume":"5","author":"A Bagherimoghaddam","year":"2022","unstructured":"Bagherimoghaddam A, Rafatpanah H, Mansouritorghabeh H (2022) Elevated levels of C3, C4, and CH50 of the complement system in ICU and non-ICU patients with COVID-19. Health Sci Rep 5:e519","journal-title":"Health Sci Rep"},{"key":"3116_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/ALN.0000000000003685","volume":"134","author":"C Heinz","year":"2021","unstructured":"Heinz C, Miesbach W, Herrmann E, Sonntagbauer M, Raimann FJ, Zacharowski K, Weber CF, Adam EH (2021) Greater fibrinolysis resistance but no greater platelet aggregation in critically ill COVID-19 patients. Anesthesiology 134:457\u2013467","journal-title":"Anesthesiology"},{"key":"3116_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jamcollsurg.2020.05.007","volume":"231","author":"FL Wright","year":"2020","unstructured":"Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer MV, Urban S, Nydam TL, Moore PK, McIntyre RC Jr (2020) Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J Am Coll Surg 231:193-203 e1","journal-title":"J Am Coll Surg"},{"key":"3116_CR18","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/17474086.2020.1831383","volume":"13","author":"M Rostami","year":"2020","unstructured":"Rostami M, Mansouritorghabeh H (2020) D-dimer level in COVID-19 infection: a systematic review. Expert Rev Hematol 13:1265\u20131275","journal-title":"Expert Rev Hematol"},{"key":"3116_CR19","doi-asserted-by":"publisher","first-page":"107602962110109","DOI":"10.1177\/10760296211010973","volume":"27","author":"R Mehrdad","year":"2021","unstructured":"Mehrdad R, Zahra K, Mansouritorghabeh H (2021) Hemostatic system (Fibrinogen level, D-Dimer, and FDP) in severe and Non-Severe patients With COVID-19: a systematic review and meta-Analysis. Clin Appl Thromb Hemost 27:10760296211010972","journal-title":"Clin Appl Thromb Hemost"},{"key":"3116_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10238-021-00769-x","volume":"22","author":"M Rostami","year":"2022","unstructured":"Rostami M, Mansouritorghabeh H, Parsa-Kondelaji M (2022) High levels of Von Willebrand factor markers in COVID-19: a systematic review and meta-analysis. Clin Exp Med 22:347\u2013357","journal-title":"Clin Exp Med"},{"key":"3116_CR21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/17474086.2022.2104708","volume":"15","author":"M Rostami","year":"2022","unstructured":"Rostami M, Mansouritorghabeh H (2022) Trend of fluctuations of antithrombin in plasma of patients with COVID-19: a meta-analysis and systematic review. Expert Rev Hematol 15:747\u2013755","journal-title":"Expert Rev Hematol"},{"key":"3116_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-024-02971-6","author":"Z Khoshnegah","year":"2024","unstructured":"Khoshnegah Z, Siyadat P, Rostami M, Sheikhi M, Ghorbani M, Mansouritorghabeh H (2024) Protein C and S activities in COVID-19: a systematic review and meta-analysis. J Thromb Thrombolysis. https:\/\/doi.org\/10.1007\/s11239-024-02971-6","journal-title":"J Thromb Thrombolysis"},{"key":"3116_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.avsg.2021.04.009","volume":"75","author":"MP Borrelli","year":"2021","unstructured":"Borrelli MP, Buora A, Scrivere P, Sponza M, Frigatti P (2021) Arterial thrombotic sequalae after COVID-19: mind the gap. Ann Vasc Surg 75:128\u2013135","journal-title":"Ann Vasc Surg"},{"key":"3116_CR24","doi-asserted-by":"publisher","first-page":"992384","DOI":"10.3389\/fimmu.2022.992384","volume":"13","author":"H Jing","year":"2022","unstructured":"Jing H, Wu X, Xiang M, Liu L, Novakovic VA, Shi J (2022) Pathophysiological mechanisms of thrombosis in acute and long COVID-19. Front Immunol 13:992384","journal-title":"Front Immunol"},{"key":"3116_CR25","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/ajh.25982","volume":"95","author":"TC Hanff","year":"2020","unstructured":"Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA (2020) Thrombosis in COVID-19. Am J Hematol 95:1578\u20131589","journal-title":"Am J Hematol"},{"key":"3116_CR26","first-page":"7","volume":"17","author":"MC Fatone","year":"2021","unstructured":"Fatone MC (2021) COVID-19: a great mime or a trigger event of autoimmune manifestations? Curr Rheumatol Rev 17:7\u201316","journal-title":"Curr Rheumatol Rev"},{"key":"3116_CR27","doi-asserted-by":"publisher","first-page":"rkaa081","DOI":"10.1093\/rap\/rkaa081","volume":"5","author":"ML Tung","year":"2021","unstructured":"Tung ML, Tan B, Cherian R, Chandra B (2021) Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots. Rheumatol Adv Practice 5:rkaa081","journal-title":"Rheumatol Adv Practice"},{"key":"3116_CR28","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/0961203317731532","volume":"27","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab N, Talathi S, Lopez-Olivo M, Suarez-Almazor M (2018) Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus 27:572\u2013583","journal-title":"Lupus"},{"key":"3116_CR29","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s11239-021-02470-y","volume":"52","author":"V Pavoni","year":"2021","unstructured":"Pavoni V, Gianesello L, Horton A (2021) Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon? J Thromb Thrombolysis 52:542\u2013552","journal-title":"J Thromb Thrombolysis"},{"key":"3116_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/art.41472","author":"E Gkrouzman","year":"2020","unstructured":"Gkrouzman E, Barbhaiya M, Erkan D, Lockshin MD (2020) Reality check on antiphospholipid antibodies in COVID-19-associated coagulopathy. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41472","journal-title":"Arthritis Rheumatol"},{"key":"3116_CR31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, de Groot PG, Koike T, Meroni PL (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295\u2013306","journal-title":"J Thromb Haemost"},{"key":"3116_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1055\/s-0042-1758118","volume":"49","author":"R Arcani","year":"2023","unstructured":"Arcani R, Cauchois R, Suchon P, Weber S, Jean R, Jarrot PA, Rey L, Venton G, Koubi M, Muller R, Bertin D, M\u00e8ge JL, Kaplanski G, Bardin N (2023) True Antiphospholipid syndrome in COVID-19: contribution of the follow-up of antiphospholipid autoantibodies. Semin Thromb Hemost 49:97\u2013102. https:\/\/doi.org\/10.1055\/s-0042-1758118","journal-title":"Semin Thromb Hemost"},{"key":"3116_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2022.100175","author":"S Zhou","year":"2022","unstructured":"Zhou S, Kaul R, Lynch KL, Wu AHB, Walker RP (2022) Transient expression of antinuclear RNP-A antibodies in patients with acute COVID-19 infection. J Translat Autoimmun. https:\/\/doi.org\/10.1016\/j.jtauto.2022.100175","journal-title":"J Translat Autoimmun"},{"key":"3116_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11082301","author":"J Alijotas-Reig","year":"2023","unstructured":"Alijotas-Reig J, Anunciaci\u00f3n-Llunell A, Morales-P\u00e9rez S, Trap\u00e9 J, Esteve-Valverde E, Miro-Mur F (2023) Thrombosis and hyperinflammation in COVID-19 acute phase are related to anti-phosphatidylserine and anti-phosphatidylinositol antibody positivity. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11082301","journal-title":"Biomedicines"},{"key":"3116_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1227547","author":"S Oba","year":"2023","unstructured":"Oba S, Hosoya T, Kaneshige R, Kawata D, Yamaguchi T, Mitsumura T, Shimada S, Shibata S, Tateishi T, Koike R, Tohda S, Hirakawa A, Yoko N, Otomo Y, Nojima J, Miyazaki Y, Yasuda S (2023) Thrombosis and antiphospholipid antibodies in Japanese COVID-19: based on propensity score matching. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1227547","journal-title":"Front Immunol"},{"key":"3116_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/20587384211042115","author":"G Gasparini","year":"2021","unstructured":"Gasparini G, Canepa P, Verdiani S, Carmisciano L, Cozzani E, De Grazia D, Andrea O, Icardi G, Parodi A (2021) A retrospective study on the prevalence of anti-phospholipid antibodies, thrombotic events and cutaneous signs of vasculopathy in 173 hospitalized COVID-19 patients. Int J Immunopathol Pharmacol. https:\/\/doi.org\/10.1177\/20587384211042115","journal-title":"Int J Immunopathol Pharmacol"},{"key":"3116_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.ABD3876","author":"Y Zuo","year":"2020","unstructured":"Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, Sule G, Gockman K, Madison JA, Zuo M, Yadav V, Wang J, Woodard W, Lezak SP, Lugogo NL, Smith SA, Morrissey JH, Kanthi Y, Knight JS (2020) Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. https:\/\/doi.org\/10.1126\/SCITRANSLMED.ABD3876","journal-title":"Sci Transl Med"},{"key":"3116_CR38","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s11239-020-02182-9","volume":"50","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Cao W, Jiang W, Xiao M, Li Y, Tang N, Liu Z, Yan X, Zhao Y, Li T, Zhu T (2020) Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. J Thromb Thrombolysis 50:580\u2013586. https:\/\/doi.org\/10.1007\/s11239-020-02182-9","journal-title":"J Thromb Thrombolysis"},{"key":"3116_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-023-02191-z","author":"SJ Lee","year":"2023","unstructured":"Lee SJ, Yoon T, Ha JW, Kim J, Lee KH, Lee JA, Kim CH, Lee SW, Kim JH, Ahn JY, Ku NS, Choi JY, Yeom JS, Jeong SJ (2023) Prevalence, clinical significance, and persistence of autoantibodies in COVID-19. Virol J. https:\/\/doi.org\/10.1186\/s12985-023-02191-z","journal-title":"Virol J"},{"key":"3116_CR40","doi-asserted-by":"publisher","first-page":"E31040","DOI":"10.1097\/MD.0000000000031040","volume":"101","author":"H Zeng","year":"2022","unstructured":"Zeng H, Cai M, Xue H, Xie W, Long X (2022) Prevalence and coagulation correlation of anticardiolipin antibodies in patients with COVID-19. Medicine 101:E31040. https:\/\/doi.org\/10.1097\/MD.0000000000031040","journal-title":"Medicine"},{"key":"3116_CR41","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00296-021-04875-7","volume":"41","author":"M Najim","year":"2021","unstructured":"Najim M, Rahhal A, Khir F, Aljundi AH, Abu Yousef S, Ibrahim F, Amer A, Mohamed AS, Saleh S, Alfaridi D, Mahfouz A, Alyafei S, Howady F, Khatib M, Alemadi SA (2021) Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study. Rheumatol Int 41:1243\u20131252. https:\/\/doi.org\/10.1007\/s00296-021-04875-7","journal-title":"Rheumatol Int"},{"key":"3116_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7759\/cureus.27862","volume":"14","author":"N Kahlon","year":"2022","unstructured":"Kahlon N, Safavi PS, Abuhelwa Z, Sheikh T, Burmeister C, Doddi S, Assaly R, Barnett W (2022) Prevalence and clinical significance of antiphospholipid antibodies in hospitalized patients with COVID-19 infection. Cureus J Med Sci 14:10. https:\/\/doi.org\/10.7759\/cureus.27862","journal-title":"Cureus J Med Sci"},{"key":"3116_CR43","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4103\/1995-7645.321611","volume":"14","author":"CS Wahono","year":"2021","unstructured":"Wahono CS, Susianti H, Dantara TWI, Rahman PA, Pratama MZ, Wulanda IA, Hartanti KD, Dewi ES, Handono K (2021) Prevalence and clinical significance of antiphospholipid antibodies among hospitalized COVID-19 patients. Asian Pac J Trop Med 14:350\u2013355. https:\/\/doi.org\/10.4103\/1995-7645.321611","journal-title":"Asian Pac J Trop Med"},{"key":"3116_CR44","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.medcli.2021.09.021","volume":"158","author":"A Rosales-Castillo","year":"2022","unstructured":"Rosales-Castillo A, Sabio JM (2022) Assessment of antiphospholipid antibodies during the follow-up of patients after SARS-CoV-2 infection. Med Clin 158:437\u2013438. https:\/\/doi.org\/10.1016\/j.medcli.2021.09.021","journal-title":"Med Clin"},{"key":"3116_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.911979","author":"G Espinosa","year":"2022","unstructured":"Espinosa G, Zamora-Mart\u00ednez C, P\u00e9rez-Isidro A, Neto D, Bravo-Gallego LY, Prieto-Gonz\u00e1lez S, Vi\u00f1as O, Moreno-Casta\u00f1o AB, Ruiz-Ortiz E, Cervera R (2022) Persistent antiphospholipid antibodies are not associated with worse clinical outcomes in a prospective cohort of hospitalised patients with SARS-CoV-2 infection. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.911979","journal-title":"Front Immunol"},{"key":"3116_CR46","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1111\/jth.15455","volume":"19","author":"A Hollerbach","year":"2021","unstructured":"Hollerbach A, M\u00fcller-Calleja N, Pedrosa D, Canisius A, Sprinzl MF, Falter T, Rossmann H, Bodenstein M, Werner C, Sagoschen I, M\u00fcnzel T, Schreiner O, Sivanathan V, Reuter M, Niermann J, Galle PR, Teyton L, Ruf W, Lackner KJ (2021) Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. J Thromb Haemost 19:2335\u20132347. https:\/\/doi.org\/10.1111\/jth.15455","journal-title":"J Thromb Haemost"},{"key":"3116_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.rpth.2023.100041","volume":"7","author":"A Mendel","year":"2023","unstructured":"Mendel A, Fritzler MJ, St-Pierre Y, Rauch J, Bernatsky S, Vinet E (2023) Outcomes associated with antiphospholipid antibodies in COVID-19: a prospective cohort study. Res Pract Thromb Haemost 7:10. https:\/\/doi.org\/10.1016\/j.rpth.2023.100041","journal-title":"Res Pract Thromb Haemost"},{"key":"3116_CR48","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1002\/art.41777","volume":"73","author":"N Gendron","year":"2021","unstructured":"Gendron N, Dragon-Durey MA, Chocron R, Darnige L, Jourdi G, Philippe A, Chenevier-Gobeaux C, Hadjadj J, Duchemin J, Khider L, Yatim N, Goudot G, Krzisch D, Debuc B, Mauge L, Levavasseur F, Pene F, Boussier J, Sourdeau E, Brichet J, Ochat N, Goulvestre C, Peronino C, Szwebel TA, Pages F, Gaussem P, Samama CM, Cheurfa C, Planquette B, Sanchez O, Diehl JL, Mirault T, Fontenay M, Terrier B, Smadja DM (2021) Lupus anticoagulant single positivity during the acute phase of COVID-19 is not associated with venous thromboembolism or in-hospital mortality. Arthritis Rheum 73:1976\u20131985. https:\/\/doi.org\/10.1002\/art.41777","journal-title":"Arthritis Rheum"},{"key":"3116_CR49","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1111\/ijlh.13334","volume":"43","author":"A Tvito","year":"2021","unstructured":"Tvito A, Ben-Chetrit E, Zimmerman FS, Asher E, Helviz Y (2021) Lupus anticoagulant in patients with COVID-19. Int J Lab Hematol 43:e17\u2013e18. https:\/\/doi.org\/10.1111\/ijlh.13334","journal-title":"Int J Lab Hematol"},{"key":"3116_CR50","doi-asserted-by":"publisher","first-page":"e12809","DOI":"10.1002\/rth2.12809","volume":"6","author":"T Noordermeer","year":"2022","unstructured":"Noordermeer T, Schutgens REG, Visser C, Rademaker E, de Maat MPM, Jansen AJG, Limper M, Cremer OL, Kruip M, Endeman H, Maas C, de Laat B, Urbanus RT (2022) Lupus anticoagulant associates with thrombosis in patients with COVID-19 admitted to intensive care units: a retrospective cohort study. Res Pract Thromb Haemost 6:e12809. https:\/\/doi.org\/10.1002\/rth2.12809","journal-title":"Res Pract Thromb Haemost"},{"key":"3116_CR51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11239-020-02335-w","volume":"52","author":"C Gazzaruso","year":"2021","unstructured":"Gazzaruso C, Mariani G, Ravetto C, Malinverni L, Tondelli E, Cerrone M, Sala V, Bevilacqua L, Altavilla T, Coppola A, Gallotti P (2021) Lupus anticoagulant and mortality in patients hospitalized for COVID-19. J Thromb Thrombolysis 52:85\u201391. https:\/\/doi.org\/10.1007\/s11239-020-02335-w","journal-title":"J Thromb Thrombolysis"},{"key":"3116_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jtauto.2021.100091","volume":"4","author":"JM Anaya","year":"2021","unstructured":"Anaya JM, Monsalve DM, Rojas M, Rodr\u00edguez Y, Montoya-Garc\u00eda N, Mancera-Navarro LM, Villadiego-Santana AM, Rodr\u00edguez-Leguizam\u00f3n G, Acosta-Ampudia Y, Ram\u00edrez-Santana C (2021) Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19. J Translat Autoimmun 4:7. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100091","journal-title":"J Translat Autoimmun"},{"key":"3116_CR53","first-page":"1024","volume":"41","author":"K Bitzogli","year":"2023","unstructured":"Bitzogli K, Jahaj E, Bakasis AD, Kapsogeorgou EK, Goules AV, Stergiou I, Pezoulas V, Antoniadou C, Skendros P, Ritis K, Fotiadis DI, Kotanidou A, Tzioufas AG, Vlachoyiannopoulos PG (2023) Incidence of autoantibodies related to systemic autoimmunity in patients with severe COVID-19 admitted to the intensive care unit. Clin Exp Rheumatol 41:1024\u20131033","journal-title":"Clin Exp Rheumatol"},{"key":"3116_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmad097","author":"S Melayah","year":"2023","unstructured":"Melayah S, Omrani N, Alouini H, Ghozzi M, Mrad S, Boussarsar M, Chaouch H, Hachfi W, Letaief A, Manka\u00ef A, Ghedira I (2023) IgA is the predominant isotype of anti-\u03b22 glycoprotein I in patients with COVID-19. Labo Med. https:\/\/doi.org\/10.1093\/labmed\/lmad097","journal-title":"Labo Med"},{"key":"3116_CR55","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s10067-020-05180-7","volume":"39","author":"C Gazzaruso","year":"2020","unstructured":"Gazzaruso C, Carlo Stella N, Mariani G, Nai C, Coppola A, Naldani D, Gallotti P (2020) High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol 39:2095\u20132097. https:\/\/doi.org\/10.1007\/s10067-020-05180-7","journal-title":"Clin Rheumatol"},{"key":"3116_CR56","first-page":"754","volume":"38","author":"M Gatto","year":"2020","unstructured":"Gatto M, Perricone C, Tonello M, Bistoni O, Cattelan AM, Bursi R, Cafaro G, de Robertis E, Mencacci A, Bozza S, Vianello A, Iaccarino L, Gerli R, Doria A, Bartoloni E (2020) Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. Clin Exp Rheumatol 38:754\u2013759","journal-title":"Clin Exp Rheumatol"},{"key":"3116_CR57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/ijpvm.ijpvm_518_21","volume":"13","author":"B Pakzad","year":"2022","unstructured":"Pakzad B, Salehi M, Abbasi S, Salehi M, Naeini M, Salehi H (2022) Evaluation of the association between antiphospholipid antibodies and ICU admission outcome in critically ill COVID-19 patients in Iranian population. Int J Preventive Med 13:4. https:\/\/doi.org\/10.4103\/ijpvm.ijpvm_518_21","journal-title":"Int J Preventive Med"},{"key":"3116_CR58","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/dna.2022.0293","volume":"42","author":"A Sadeghi","year":"2023","unstructured":"Sadeghi A, Hasanlu M, Feyzi A, Mansori K, Ghodrati S, Parsamanesh N (2023) Evaluating the relationship between antiphospholipid antibodies and COVID-19 severity. DNA Cell Biol 42:65\u201371. https:\/\/doi.org\/10.1089\/dna.2022.0293","journal-title":"DNA Cell Biol"},{"key":"3116_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134370","author":"NV Dolgushina","year":"2023","unstructured":"Dolgushina NV, Menzhinskaya IV, Ermakova DM, Frankevich NA, Vtorushina VV, Sukhikh GT (2023) The effect of COVID-19 severity, associated serum autoantibodies and time interval after the disease on the outcomes of fresh oocyte ART cycles in non-vaccinated patients. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12134370","journal-title":"J Clin Med"},{"key":"3116_CR60","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.thromres.2023.01.016","volume":"223","author":"K Wojcik","year":"2023","unstructured":"Wojcik K, Bazan-Socha S, Celejewska-W\u00f3jcik N, G\u00f3rka K, Licholai S, Polok K, Stachura T, Zareba L, Dziedzic R, Gradzikiewicz A, Sanak M, Musial J, Sladek K, Iwaniec T (2023) Decreased protein C activity, lower ADAMTS13 antigen and free protein S levels accompanied by unchanged thrombin generation potential in hospitalized COVID-19 patients. Thromb Res 223:80\u201386. https:\/\/doi.org\/10.1016\/j.thromres.2023.01.016","journal-title":"Thromb Res"},{"key":"3116_CR61","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/cts.12908","volume":"14","author":"S Pascolini","year":"2021","unstructured":"Pascolini S, Vannini A, Deleonardi G, Ciordinik M, Sensoli A, Carletti I, Veronesi L, Ricci C, Pronesti A, Mazzanti L, Grondona A, Silvestri T, Zanuso S, Mazzolini M, Lalanne C, Quarneti C, Fusconi M, Giostra F, Granito A, Muratori L, Lenzi M, Muratori P (2021) COVID-19 and immunological dysregulation: can autoantibodies be useful? Clin Transl Sci 14:502\u2013508. https:\/\/doi.org\/10.1111\/cts.12908","journal-title":"Clin Transl Sci"},{"key":"3116_CR62","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3855\/jidc.15423","volume":"16","author":"E Atalar","year":"2022","unstructured":"Atalar E, Erden A, Guven SC, Armagan B, Ates I, K\u00fc\u00e7\u00fcksahin O, Omma A (2022) The clinical significance of antiphospholipid antibodies in COVID-19 infection. J Infect Dev Ctries 16:276\u2013282. https:\/\/doi.org\/10.3855\/jidc.15423","journal-title":"J Infect Dev Ctries"},{"key":"3116_CR63","doi-asserted-by":"publisher","first-page":"10","DOI":"10.11604\/pamj.2022.42.110.33020","volume":"42","author":"A Ben Bnina","year":"2022","unstructured":"Ben Bnina A, Ben Dhia R, Gnaba S, Annabi A, Chouchane S, Naija W, Said H, Oueslati A, Bouatay A (2022) Assessment of antiphospholipid antibodies profiles based on severity of COVID-19 pneumonia. Pan Afr Med J 42:10. https:\/\/doi.org\/10.11604\/pamj.2022.42.110.33020","journal-title":"Pan Afr Med J"},{"key":"3116_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24004","author":"A Lee","year":"2021","unstructured":"Lee A, Nahm CH, Lee JS, Lee MK, Lee KR (2021) Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID-19. J Clin Lab Anal. https:\/\/doi.org\/10.1002\/jcla.24004","journal-title":"J Clin Lab Anal"},{"key":"3116_CR65","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/art.41425","volume":"72","author":"M Xiao","year":"2020","unstructured":"Xiao M, Zhang Y, Zhang S, Qin X, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C, Zhao J, Sun X, Tian R, Wu W, Wu D, Ma J, Chen Y, Zhang D, Xie J, Yan X, Zhou X, Liu Z, Wang J, Du B, Qin Y, Gao P, Lu M, Hou X, Wu X, Zhu H, Xu Y, Zhang W, Li T, Zhang F, Zhao Y, Li Y, Zhang S (2020) Antiphospholipid Antibodies in Critically Ill Patients With COVID-19. Arthritis Rheum 72:1998\u20132004. https:\/\/doi.org\/10.1002\/art.41425","journal-title":"Arthritis Rheum"},{"key":"3116_CR66","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/14397595.2021.1892257","volume":"32","author":"S Karahan","year":"2022","unstructured":"Karahan S, Erol K, Yuksel RC, Artan C, Celik I (2022) Antiphospholipid antibodies in COVID-19-associated pneumonia patients in intensive care unit. Mod Rheumatol 32:163\u2013168. https:\/\/doi.org\/10.1080\/14397595.2021.1892257","journal-title":"Mod Rheumatol"},{"key":"3116_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269466","author":"R Shah","year":"2022","unstructured":"Shah R, Mohammed YN, Koehler TJ, Kaur J, Toufeili M, Pulipati P, Alqaysi A, Khan A, Khalid M, Lee Y, Dhillon P, Dan AT, Kumar N, Bowen M, Sule AA, Krishnamoorthy G (2022) Antiphospholipid antibodies and vitamin D deficiency in COVID-19 infection with and without venous or arterial thrombosis: a pilot case-control study. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0269466","journal-title":"PLoS One"},{"key":"3116_CR68","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/biomedicines11123117","volume":"11","author":"M Zlatkovic-Svenda","year":"2023","unstructured":"Zlatkovic-Svenda M, Ovuka M, Ogric M, Cucnik S, Zigon P, Radivcev A, Zdravkovic M, Radunovic G (2023) Antiphospholipid antibodies and vascular thrombosis in patients with severe forms of COVID-19. Biomedicines 11:13. https:\/\/doi.org\/10.3390\/biomedicines11123117","journal-title":"Biomedicines"},{"key":"3116_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102729","author":"A Le Joncour","year":"2021","unstructured":"Le Joncour A, Frere C, Martin-Toutain I, Gougis P, Ghillani-Dalbin P, Maalouf G, Vieira M, Marcelin AG, Salem JE, Allenbach Y, Saadoun D, Benveniste O, Cacoub P (2021) Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. Autoimmun Rev. https:\/\/doi.org\/10.1016\/j.autrev.2020.102729","journal-title":"Autoimmun Rev"},{"key":"3116_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687534","author":"S Sciascia","year":"2021","unstructured":"Sciascia S, Radin M, Bazzan M, Montaruli B, Cosseddu D, Norbiato C, Bertero MT, Carignola R, Bacco B, Gallo Cassarino S, Roccatello D (2021) antiphospholipid antibodies and infection: non nova sed nove. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.687534","journal-title":"Front Immunol"},{"key":"3116_CR71","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/art.41409","volume":"72","author":"D Bertin","year":"2020","unstructured":"Bertin D, Brodovitch A, Beziane A, Hug S, Bouamri A, Mege JL, Heim X, Bardin N (2020) Anticardiolipin IgG autoantibody level is an independent risk factor for COVID-19 severity. Arthritis Rheum 72:1953\u20131955. https:\/\/doi.org\/10.1002\/art.41409","journal-title":"Arthritis Rheum"},{"key":"3116_CR72","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1136\/annrheumdis-2021-220206","volume":"80","author":"U Trahtemberg","year":"2021","unstructured":"Trahtemberg U, Rottapel R, Dos Santos CC, Slutsky AS, Baker A, Fritzler MJ (2021) Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients. Ann Rheum Dis 80:1236\u20131240. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220206","journal-title":"Ann Rheum Dis"},{"key":"3116_CR73","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.amjms.2022.10.012","volume":"365","author":"G Garcia-Arellano","year":"2023","unstructured":"Garcia-Arellano G, Camacho-Ortiz A, Moreno-Arquieta IA, Cardenas-de la Garza JA, Rubio-Torres DC, Garza-Gonzalez E, Bocanegra-Ibarias P, Galarza-Delgado DA (2023) Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19. Am J Med Sci 365:215\u20137. https:\/\/doi.org\/10.1016\/j.amjms.2022.10.012","journal-title":"Am J Med Sci"},{"key":"3116_CR74","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s43166-021-00105-x","volume":"49","author":"OI Badr","year":"2022","unstructured":"Badr OI, Elrefaey WA, Abu-Zaid MH, Elmedany SH (2022) Anti-phospholipid antibodies in the setting of thromboembolic events associated with severe COVID-19 pneumonia. Egypt Rheumatol Rehabil 49:10. https:\/\/doi.org\/10.1186\/s43166-021-00105-x","journal-title":"Egypt Rheumatol Rehabil"},{"key":"3116_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584241","author":"MO Borghi","year":"2020","unstructured":"Borghi MO, Beltagy A, Garrafa E, Curreli D, Cecchini G, Bodio C, Grossi C, Blengino S, Tincani A, Franceschini F, Andreoli L, Lazzaroni MG, Piantoni S, Masneri S, Crisafulli F, Brugnoni D, Muiesan ML, Salvetti M, Parati G, Torresani E, Mahler M, Heilbron F, Pregnolato F, Pengo M, Tedesco F, Pozzi N, Meroni PL (2020) Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.584241","journal-title":"Front Immunol"},{"key":"3116_CR76","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/biomedicines9080899","volume":"9","author":"FJ Gil-Etayo","year":"2021","unstructured":"Gil-Etayo FJ, Garcinu\u00f1o S, Lalueza A, D\u00edaz-Sim\u00f3n R, Garc\u00eda-Reyne A, Pleguezuelo DE, Cabrera-Marante O, Rodriguez-Frias EA, Perez-Rivilla A, Serrano M, Serrano A (2021) Anti-phospholipid antibodies and COVID-19 thrombosis: a co-star not a supporting actor. Biomedicines 9:16. https:\/\/doi.org\/10.3390\/biomedicines9080899","journal-title":"Biomedicines"},{"key":"3116_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-15969-y","author":"D Bertin","year":"2022","unstructured":"Bertin D, Brodovitch A, Lopez A, Arcani R, Thomas GM, Beziane A, Weber S, Babacci B, Heim X, Rey L, Leone M, Mege JL, Bardin N (2022) Anti-cardiolipin IgG autoantibodies associate with circulating extracellular DNA in severe COVID-19. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-022-15969-y","journal-title":"Sci Rep"},{"key":"3116_CR78","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fmed.2022.934270","volume":"9","author":"MI Stjepanovic","year":"2022","unstructured":"Stjepanovic MI, Stojanovic MR, Stankovic S, Cvejic J, Dimic-Janjic S, Popevic S, Buha I, Belic S, Djurdjevic N, Stjepanovic MM, Jovanovic D, Stojkovic-Lalosevic M, Soldatovic I, Bonaci-Nikolic B, Miskovic R (2022) Autoimmune and immunoserological markers of COVID-19 pneumonia: can they help in the assessment of disease severity. Front Med 9:11. https:\/\/doi.org\/10.3389\/fmed.2022.934270","journal-title":"Front Med"},{"key":"3116_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11051241","author":"A Dima","year":"2023","unstructured":"Dima A, Popescu DN, Moroti R, Stoica E, State G, Negoi F, Berza IA, Parvu M (2023) antiphospholipid antibodies occurrence in acute SARS-CoV-2 infection without overt thrombosis. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11051241","journal-title":"Biomedicines"},{"issue":"2","key":"3116_CR80","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/ijlh.14224","volume":"46","author":"R Mize","year":"2024","unstructured":"Mize R, Mueller S, Roth M, Montgomery G, Battinelli EM, Uljon S (2024) False positive lupus anticoagulant tests in patients with high C-reactive protein: a comparison of two hexagonal phase reagents. Int J Lab Hematol 46(2):411\u2013414","journal-title":"Int J Lab Hematol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03116-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03116-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03116-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:28:07Z","timestamp":1762939687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03116-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":80,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["3116"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03116-z","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]},"assertion":[{"value":"13 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. Mettine H.A. Bos has received research funding from NovoNordisk, Health Care Agency and F. Hoffmann-LaRoche ltd., consulting fee for Varmx B.V. (all unrelated to this work).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval number: IR.MUMS.REC.1403.138","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}